PL2654785T3 - Wzmocniona odpowiedź immunologiczna u gatunków wołowatych - Google Patents

Wzmocniona odpowiedź immunologiczna u gatunków wołowatych

Info

Publication number
PL2654785T3
PL2654785T3 PL11804675T PL11804675T PL2654785T3 PL 2654785 T3 PL2654785 T3 PL 2654785T3 PL 11804675 T PL11804675 T PL 11804675T PL 11804675 T PL11804675 T PL 11804675T PL 2654785 T3 PL2654785 T3 PL 2654785T3
Authority
PL
Poland
Prior art keywords
immune response
enhanced immune
bovine species
bovine
species
Prior art date
Application number
PL11804675T
Other languages
English (en)
Inventor
Albert Abraham
Daniel Keil
Jason NICKELL
Christian Weiss
Original Assignee
Bayer Intellectual Property Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Intellectual Property Gmbh filed Critical Bayer Intellectual Property Gmbh
Publication of PL2654785T3 publication Critical patent/PL2654785T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/711Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/102Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/55Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552Veterinary vaccine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55555Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55566Emulsions, e.g. Freund's adjuvant, MF59
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL11804675T 2010-12-22 2011-12-20 Wzmocniona odpowiedź immunologiczna u gatunków wołowatych PL2654785T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201061426255P 2010-12-22 2010-12-22
EP11804675.4A EP2654785B1 (en) 2010-12-22 2011-12-20 Enhanced immune response in bovine species
PCT/EP2011/073414 WO2012084951A1 (en) 2010-12-22 2011-12-20 Enhanced immune response in bovine species

Publications (1)

Publication Number Publication Date
PL2654785T3 true PL2654785T3 (pl) 2019-09-30

Family

ID=45444595

Family Applications (1)

Application Number Title Priority Date Filing Date
PL11804675T PL2654785T3 (pl) 2010-12-22 2011-12-20 Wzmocniona odpowiedź immunologiczna u gatunków wołowatych

Country Status (35)

Country Link
US (3) US20130295167A1 (pl)
EP (1) EP2654785B1 (pl)
JP (2) JP6058550B2 (pl)
KR (1) KR101940826B1 (pl)
CN (2) CN108379576A (pl)
AR (1) AR084510A1 (pl)
AU (1) AU2011347464B2 (pl)
BR (1) BR112013016231B1 (pl)
CA (1) CA2822359C (pl)
CL (1) CL2013001833A1 (pl)
CO (1) CO6761354A2 (pl)
CR (1) CR20130312A (pl)
DK (1) DK2654785T3 (pl)
DO (1) DOP2013000149A (pl)
EC (1) ECSP13012709A (pl)
ES (1) ES2722204T3 (pl)
GT (1) GT201300168A (pl)
HK (1) HK1259341A1 (pl)
HR (1) HRP20190779T1 (pl)
HU (1) HUE043473T4 (pl)
IL (1) IL226733B (pl)
LT (1) LT2654785T (pl)
MX (1) MX345854B (pl)
MY (1) MY167159A (pl)
NZ (1) NZ612285A (pl)
PH (1) PH12013501348B1 (pl)
PL (1) PL2654785T3 (pl)
PT (1) PT2654785T (pl)
RU (1) RU2606855C2 (pl)
SI (1) SI2654785T1 (pl)
TR (1) TR201906323T4 (pl)
TW (1) TWI587877B (pl)
UA (1) UA118537C2 (pl)
UY (1) UY33821A (pl)
WO (1) WO2012084951A1 (pl)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2654785T3 (pl) 2010-12-22 2019-09-30 Bayer Intellectual Property Gmbh Wzmocniona odpowiedź immunologiczna u gatunków wołowatych
JO3733B1 (ar) 2011-04-05 2021-01-31 Bayer Ip Gmbh استخدام 3,2-دايهيدروايميدازو[1, 2 -c]كوينازولينات مستبدلة
EP3110940A1 (en) * 2014-02-28 2017-01-04 Bayer Animal Health GmbH Immunostimulatory plasmids
CN104825393B (zh) * 2015-01-16 2017-11-10 艾美科健(中国)生物医药有限公司 一种硫酸头孢喹肟肺靶向脂质体制剂及其制备方法
JP2018518511A (ja) * 2015-06-26 2018-07-12 バイエル・アニマル・ヘルス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングBayer Animal Health Gmbh 細胞質dna監視分子の調節方法
US11439703B2 (en) * 2015-07-31 2022-09-13 ELANCO US, Inc. Enhanced immune response in porcine species
KR20180035860A (ko) * 2015-07-31 2018-04-06 바이엘 애니멀 헬스 게엠베하 수생 종에서의 향상된 면역 반응
US10933131B2 (en) * 2016-07-26 2021-03-02 Bayer Animal Health Gmbh Increased fertility in bovine species
KR102069670B1 (ko) * 2017-03-02 2020-01-23 단디바이오사이언스 주식회사 면역활성물질을 포함하는 다중도메인캡슐, 이의 제조방법, 및 이를 포함하는 면역조절 조성물
KR20200099556A (ko) 2017-12-15 2020-08-24 바이엘 애니멀 헬스 게엠베하 면역자극성 조성물
CN108812546A (zh) * 2018-09-07 2018-11-16 四川省草原科学研究院 适于青藏高原地区牦牛运输减少应激的药物及使用方法
CN109646435B (zh) * 2019-01-11 2021-08-03 山东省农业科学院奶牛研究中心 厄他培南钠在制备防治牛传染性鼻气管炎药物中的应用
US11689594B2 (en) 2019-03-28 2023-06-27 Nec Corporation Information processing apparatus, server allocation apparatus, method, and computer readable medium
CN114480663A (zh) * 2021-11-15 2022-05-13 贵州省畜牧兽医研究所 用于检测猪源差异脲原体的引物对、试剂盒及检测方法

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3854480A (en) 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
US4675189A (en) 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
US4452775A (en) 1982-12-03 1984-06-05 Syntex (U.S.A.) Inc. Cholesterol matrix delivery system for sustained release of macromolecules
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US5133974A (en) 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US5407686A (en) 1991-11-27 1995-04-18 Sidmak Laboratories, Inc. Sustained release composition for oral administration of active ingredient
US5427791A (en) 1992-08-05 1995-06-27 Regents Of The University Of Minnesota Embryonal vaccine against Newcastle disease
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6429199B1 (en) 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
US5830878A (en) * 1995-06-07 1998-11-03 Megabios Corporation Cationic lipid: DNA complexes for gene targeting
US5736152A (en) 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
US6048535A (en) 1997-06-12 2000-04-11 Regents Of The University Of Minnesota Multivalent in ovo avian vaccine
US20030022854A1 (en) * 1998-06-25 2003-01-30 Dow Steven W. Vaccines using nucleic acid-lipid complexes
US6693086B1 (en) 1998-06-25 2004-02-17 National Jewish Medical And Research Center Systemic immune activation method using nucleic acid-lipid complexes
US20040247662A1 (en) 1998-06-25 2004-12-09 Dow Steven W. Systemic immune activation method using nucleic acid-lipid complexes
JP4800485B2 (ja) 1999-03-26 2011-10-26 バイカル インコーポレイテッド ポリヌクレオチドベースのワクチンに対する免疫応答を増強するためのアジュバント組成物および方法
RU2158587C1 (ru) * 1999-05-11 2000-11-10 Ставропольское научно-производственное объединение "Пульс" Антибактериальное средство для лечения заболеваний сельскохозяйственных животных и птиц, способ профилактики и лечения цыплят при заболеваниях бактериальной этиологии, способ лечения респираторной болезни телят бактериальной этиологии, способ профилактики туберкулеза у крупного рогатого скота
US20040002472A1 (en) * 2000-01-21 2004-01-01 Audonnet Jean-Christophe Francis Vaccination or immunization using a prime-boost regimen
PE20020572A1 (es) * 2000-12-06 2002-07-31 Centro Inmunologia Molecular Preparaciones para potenciar la inmunogenicidad de antigenos poco inmunogenicos
OA13092A (en) 2001-04-24 2006-11-10 Innogenetics Nv Constructs and methods for expression of recombinant HCV envelope proteins.
WO2003004051A2 (en) * 2001-07-02 2003-01-16 Pfizer Products Inc. Mycoplasma hyopneumoniae vaccine and methods for reducing mycoplasma bovis pneumonia in cattle
PL1605971T3 (pl) * 2003-03-26 2010-10-29 Wyeth Llc Kompozycja immunogenna i sposoby
PE20050386A1 (es) * 2003-05-29 2005-06-23 Schering Plough Ltd Composiciones farmaceuticas de florfenicol
WO2005034979A2 (en) * 2003-10-11 2005-04-21 Inex Pharmaceuticals Corporation Methods and compositions for enhancing innate immunity and antibody dependent cellular cytotoxicity
US20090068223A1 (en) 2005-11-15 2009-03-12 Boehringer Ingelheim Vetmedica, Inc. Combination vaccine comprising an attenuated bovine viral diarrhea virus
JP2008094763A (ja) * 2006-10-12 2008-04-24 Takeshi Ogura 海洋ミネラル成分からなるインターフェロンγ産生増強剤
WO2009105283A1 (en) * 2008-02-24 2009-08-27 Govt. Of The United States Of America, As Represented By The Sec., Dept. Of Health And Human Service Use of immunogenic compositions for the treatment or prevention of pathogen infections
US8945590B2 (en) * 2008-03-25 2015-02-03 Juvaris Biotherapeutics, Inc. Enhancement of an immune response by administration of a cationic lipid-DNA complex (CLDC)
WO2010051210A1 (en) * 2008-10-31 2010-05-06 Boehringer Ingelheim Vetmedica, Inc. Use of various antigens including antigens from mycoplasma bovis in multivalent vaccine composition
ES2550181T3 (es) * 2009-05-14 2015-11-05 Bayer Intellectual Property Gmbh Respuesta inmunitaria reforzada en especies aviares
PL2654785T3 (pl) * 2010-12-22 2019-09-30 Bayer Intellectual Property Gmbh Wzmocniona odpowiedź immunologiczna u gatunków wołowatych

Also Published As

Publication number Publication date
US10751361B2 (en) 2020-08-25
MX345854B (es) 2017-02-17
CR20130312A (es) 2013-10-17
HK1259341A1 (zh) 2019-11-29
JP2017036290A (ja) 2017-02-16
GT201300168A (es) 2015-02-23
SI2654785T1 (sl) 2019-06-28
RU2606855C2 (ru) 2017-01-10
BR112013016231B1 (pt) 2021-03-23
RU2013133730A (ru) 2015-01-27
TWI587877B (zh) 2017-06-21
HUE043473T4 (hu) 2019-12-30
CA2822359C (en) 2021-06-01
AU2011347464B2 (en) 2016-08-25
TW201306877A (zh) 2013-02-16
US20190201434A1 (en) 2019-07-04
TR201906323T4 (tr) 2019-05-21
US20140010865A1 (en) 2014-01-09
DOP2013000149A (es) 2013-08-15
CO6761354A2 (es) 2013-09-30
PT2654785T (pt) 2019-06-25
NZ612285A (en) 2015-09-25
JP2014500292A (ja) 2014-01-09
MY167159A (en) 2018-08-13
AR084510A1 (es) 2013-05-22
CN108379576A (zh) 2018-08-10
CA2822359A1 (en) 2012-06-28
JP6058550B2 (ja) 2017-01-11
KR20130132926A (ko) 2013-12-05
DK2654785T3 (da) 2019-06-24
KR101940826B1 (ko) 2019-01-21
HUE043473T2 (hu) 2019-08-28
ES2722204T3 (es) 2019-08-08
ECSP13012709A (es) 2013-08-30
CN103501810A (zh) 2014-01-08
UY33821A (es) 2012-07-31
AU2011347464A1 (en) 2013-07-11
PH12013501348B1 (en) 2019-11-22
LT2654785T (lt) 2019-07-10
UA118537C2 (uk) 2019-02-11
WO2012084951A1 (en) 2012-06-28
HRP20190779T1 (hr) 2019-06-28
US20130295167A1 (en) 2013-11-07
IL226733B (en) 2020-06-30
EP2654785B1 (en) 2019-03-20
BR112013016231A2 (pt) 2016-09-27
EP2654785A1 (en) 2013-10-30
CL2013001833A1 (es) 2014-06-20
AU2011347464A2 (en) 2013-08-22
MX2013007064A (es) 2013-08-21
PH12013501348A1 (en) 2013-08-28

Similar Documents

Publication Publication Date Title
PH12013501348A1 (en) Enhanced immune response in bovine species
ZA201307919B (en) Composition and method for enhancing an immune response
GB2481482B (en) Improvements in sensors
IL230511A0 (en) 4-Imidazopyridazine-1-yl-benzamides and 4-imidazotriazine-1-yl-benzamides as btk inhibitors
PT2665818T (pt) Expressão de proteínas em plantas
ZA201107827B (en) Enhanced immune response in avian species
PT2594282E (pt) Lactoferrina e a matéria branca
GB2490393B (en) Improvements in sensors
EP2521787A4 (en) IMPROVED PROTEIN EXPRESSION
GB201321941D0 (en) Title in Foreign
GB201001966D0 (en) All in one pot stop
GB201014323D0 (en) Improvements in semiconductor processing
GB201016990D0 (en) Improvements in swimfeeder devices
GB201001384D0 (en) Light-fitting and associated methods
GB201100062D0 (en) Improvements in ventilation
ME03310B (me) 4-IMIDAZOPIRIDAZIN-1-jL-BENZAMIDI I 4-IMIDAZOTRIAZIN-1-IL-BENZAMIDl КАО INHIBITORI втк